ANIP in the 13F filings
Ani Pharmaceuticals Inc · CUSIP 00182C103
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 31
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 6 listed it in both
- Shares listed
- 3,165,830
- combined, among listed positions
- Reported value
- $250m
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 16 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -129,627.
Managers listing ANIP in Q4 2025
31 of 31 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 539,665 shares now+474,420
- Schonfeld Strategic Advisors LLCexisting position · 192,006 shares now+170,206
- Two Sigma Investments LPexisting position · 181,151 shares now+127,368
- Arrowstreet Capital LPexisting position · 473,207 shares now+113,029
- Freestone Grove Partners LPexisting position · 141,109 shares now+110,425
Reductions
- Citadel Advisors LLCexisting position · 20,415 shares now-559,670
- Point72 Asset Management LPexisting position · 121,211 shares now-277,881
- Jane Street Group LLCexisting position · 25,657 shares now-108,782
- Walleye Capital LLCexisting position · 117,307 shares now-99,000
- Balyasny Asset Management LLCexisting position · 205,089 shares now-81,060
New positions and exits
New (1)
Exited (2)
- Voloridge Investment Management LLCwas $277k
- Acadian Asset Management LLCwas $35k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2014 | 1 | $941k | n.a. | n.a. |
| Q4 2014 | 3 | $3.9m | n.a. | n.a. |
| Q1 2015 | 1 | $769k | n.a. | n.a. |
| Q2 2015 | 1 | $434k | n.a. | n.a. |
| Q3 2015 | 1 | $3.1m | n.a. | n.a. |
| Q1 2020 | 1 | $670k | n.a. | n.a. |
| Q2 2020 | 1 | $299k | n.a. | n.a. |
| Q4 2021 | 1 | $252k | n.a. | n.a. |
| Q3 2023 | 1 | $232k | n.a. | n.a. |
| Q1 2024 | 1 | $319k | 1 | 0 |
| Q2 2024 | 1 | $1.2m | 1 | 0 |
| Q3 2024 | 1 | $9.3m | 1 | 1 |
| Q4 2024 | 1 | $259k | n.a. | n.a. |
| Q1 2025 | 2 | $11m | 1 | 1 |
| Q2 2025 | 2 | $16m | 2 | 0 |
| Q3 2025 | 6 | $71m | 4 | 1 |
| Q4 2025 | 5 | $35m | 15 | 16 |
| Q1 2026 | 5 | $52m | 15 | 15 |
| Q2 2026 | 3 | $17m | 8 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ANIP and LLY →ANIP and JNJ →ANIP and VRTX →Choose a stock to compare with ANIP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ANIP, latest filings →Back to the 13F Explorer →